Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (6607)	4/21/1999 12:35:00 PM
From: biowa	Respond to of 9719

Rocket, That and alot of strategy work. How about yourself? I see your profile lists you as a consultant; still haven't been seduced back into the office, huh? I figured I better come back before the tech stocks melt down and fund managers actually think of investing in something that doesn't require a modem. Sorry, just being delirious, the heat in the desert got to me for a minute. biowa

To: Rocketman who wrote (6607)	4/22/1999 7:16:00 PM
From: aknahow	Read Replies (1) \| Respond to of 9719

O.T. an informed opinion on the validity of the following statement would be appreciated. xoma.com "XOMA's Human Engineering (HE) technology presents a new paradigm for antibody humanization, a novel alternative to CDR-grafting methods. The XOMA method uses a unique residue-by-residue analysis to determine which amino acid residues along the non-human antibody variable region can be humanized and which need to remain non-human in order to preserve binding affinity and proper protein folding." If this statement is off the mark and not correct, I would like to know it. The use of the phrase, "new paradigm", is a bit out of corporate character for XOMA.